ISSN:
1573-0646
Keywords:
phase II
;
lymphoma
;
menogaril
;
chemotherapy
;
low grade
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug has only modest activity in this potentially responsive group of patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00194551
Permalink